Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
CAMBRIDGE, Mass., Oct. 06, 2017 -- Spero Therapeutics, Inc. (“Spero”), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections, today announced that it has publicly filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (the “SEC”) relating to a proposed initial public offering of shares of its common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. Spero has applied to list its common stock on The NASDAQ Global Market under the ticker symbol “SPRO.”
BofA Merrill Lynch, Cowen and Stifel will act as joint book-running managers for the proposed offering. Oppenheimer & Co. will act as a co-manager.
The proposed offering will be made only by means of a prospectus. Copies of the preliminary prospectus, when available, may be obtained from BofA Merrill Lynch, NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte, NC 28255-0001, Attention: Prospectus Department, or by email at [email protected]; from Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attention: Prospectus Department, or by telephone at (631) 274-2806; and from Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, or by telephone at (415) 364-2720 or by email at [email protected].
A registration statement relating to these securities has been filed with the SEC, but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Spero
Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections.
Spero Media and Investor Contact:
Stern Investor Relations
Beth DelGiacco, Vice President
212-362-1200
[email protected]
